New obesity drug CagriSema tested against diet in metabolism study
NCT ID NCT07184086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares the experimental drug CagriSema (cagrilintide and semaglutide) to a calorie-reduced diet in 80 adults with obesity. It measures how each approach changes the body's energy use, like sleeping metabolic rate. The study lasts about 1.5 years, and all participants will eventually receive CagriSema. This is a Phase 1 trial, so the drug is not yet available by prescription.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advent Health-Res Inst
RECRUITINGOrlando, Florida, 32804, United States
-
Pennington Biomed Res Ctr
RECRUITINGBaton Rouge, Louisiana, 70808-4124, United States